1. Segal, D. M., Urch, C. E., George, A. J. T., and Jost, C. R. (1992) Bispecific antibodies in cancer treatment, inBiologic Therapy of Cancer Updates (DeVita, V. T., Jr, Hellman, S., and Rosenberg, S. A., eds.), Lippincott, Philadelphia, pp. 1–12.
2. Segal, D. M., Jost, C. R., and George, A. J. T. (1993) Targeted cellular cytotoxicity, inCytotoxic Cells: Generation, Recognition, Effector Functions, Methods (Sitkovsky, M. V., Henkart, P. A., eds.), Burkhauser, Boston, pp. 96–110.
3. Perez, P., Hoffman, R. W., Titus, J. A., and Segal, D. M. (1986) Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies.J. Exp. Med. 163, 166–178.
4. Qian, J. H., Titus, J. A., Andrew, S. M., Mezzanzanica, D., Garrido, M. A., Wunderlich, J. R., and Segal, D. M. (1991) Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth.J. Immunol. 146, 3250–3256.
5. Karpovsky, B., Titus, J. A., Stephany, D. A., and Segal, D. M. (1984) Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fcγ receptor anti-bodies.J. Exp. Med. 160, 1686–1701.